אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - estetrol monohydrate, quantity: 15 mg (equivalent: estetrol, qty 14.2 mg); drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: magnesium stearate; titanium dioxide; hypromellose; hyprolose; purified talc; hydrogenated cottonseed oil; lactose monohydrate; maize starch - nextstellis is indicated for use by women of reproductive potential to prevent pregnancy.

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

gedeon richter plc. - drospirenone, estetrol monohydrate - contraceptives, oral - sex hormones and modulators of the genital system, - oral contraceptive

ארצות הברית - אנגלית - NLM (National Library of Medicine)

mayne pharma - drospirenone (unii: n295j34a25) (drospirenone - unii:n295j34a25), estetrol monohydrate (unii: kc3gi9um9v) (estetrol - unii:enb39r14vf) - nextstellis is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use nextstellis may be less effective in females with a bmi ≥ 30 kg/m2 . in females with bmi ≥ 30 kg/m2 , decreasing effectiveness may be associated with increasing bmi [see clinical studies (14)]. nextstellis is contraindicated in females who are known to have or develop the following conditions: - a history of, increased risk for, or current arterial or venous thrombotic/thromboembolic diseases. examples include females who are known to: - smoke, if 35 years of age and older [see boxed warning and warnings and precautions (5.1)] - have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1)] - have cerebrovascular disease [see warnings and precautions (5.1)] - have coronary artery disease [see warnings and precautions (5.1)] - have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with v

האיחוד האירופי - אנגלית - EMA (European Medicines Agency)

estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - sex hormones and modulators of the genital system, - oral contraception.the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4.3 and 4.4).

קנדה - אנגלית - Health Canada

searchlight pharma inc - estetrol monohydrate; drospirenone - tablet - 15mg; 3mg - estetrol monohydrate 15mg; drospirenone 3mg - contraceptives

ישראל - אנגלית - Ministry of Health

dexcel ltd, israel - drospirenone; estetrol as monohydrate - film coated tablets - drospirenone 3 mg; estetrol as monohydrate 14.2 mg - drospirenone and estetrol - nextela is indicated for oral contraception

בנגלדש - אנגלית - DGDA (Directorate General of Drug Administration)

nuvista pharma ltd - drospirenone + estetrol - tablet - 3 mg + 14.2 mg

בנגלדש - אנגלית - DGDA (Directorate General of Drug Administration)

renata limited - drospirenone + estetrol - tablet - 3 mg + 14.2 mg

ארצות הברית - אנגלית - NLM (National Library of Medicine)

akorn - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 40 mg in 1 ml - megestrol acetate oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). history of hypersensitivity to megestrol acetate or any component of the formulation. known or suspected pregnancy.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

physicians total care, inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate 40 mg - megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). it should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. history of hypersensitivity to megestrol acetate or any component of the formulation.